# Qatar Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Qatar HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Qatar (QAT)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $9.4M
- Products: 23
- Buyer markets: 21
- Average CAGR: +3.2%
- Global sector size: $415.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $247.3B | $325.0K | $90.8B | +1.1% | 13 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.5B | $560.7K | $20.3B | +19.4% | 11 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $35.2B | $123.2 | $12.4B | -17.6% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $11.6B | $13.4 | $11.4B | -41.6% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $19.3B | $8.4K | $11.0B | -6.2% | 5 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $16.0B | $8.7K | $7.8B | +1.3% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $13.1B | $19.5K | $6.2B | +5.2% | 3 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $17.8 | $4.9B | -5.3% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $5.9K | $4.1B | -11.2% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $4.8B | $1.4 | $2.8B | -34.0% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $2.8B | $319.0 | $2.6B | +1.3% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $64.3 | $2.1B | +20.4% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $4.3B | $16.5K | $2.0B | +85.0% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $136.5 | $2.0B | -6.5% | 1 | +0.0% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $102.1K | $1.3B | +16.0% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $2.0B | $8.3M | $1.3B | +4.7% | 1 | +0.5% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $23.6 | $1.3B | -7.0% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $187.4 | $1.1B | -4.1% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $17.1K | $1.0B | +11.7% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $669.2M | $60.2K | $1.0B | +31.3% | 1 | +0.0% |
| HS 320611 - Colouring matter: pigments and preparations based on titanium dioxide, containing 80% or more by weight of titanium dioxide calculated on the dry matter | $1.1B | $3.1 | $997.2M | -96.6% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $44.6K | $989.9M | +177.0% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $1.3 | $981.1M | -25.3% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $40.0B calculated opportunity across 9 products.
- Switzerland, Liechtenstein (CHE): $30.4B calculated opportunity across 2 products.
- Germany (DEU): $23.4B calculated opportunity across 9 products.
- Netherlands (NLD): $20.3B calculated opportunity across 6 products.
- Belgium (BEL): $16.1B calculated opportunity across 3 products.
- United Kingdom (GBR): $8.1B calculated opportunity across 3 products.
- China (CHN): $7.1B calculated opportunity across 2 products.
- Spain (ESP): $6.6B calculated opportunity across 2 products.
- France (FRA): $6.5B calculated opportunity across 3 products.
- Canada (CAN): $6.1B calculated opportunity across 3 products.
- Italy (ITA): $4.9B calculated opportunity across 1 products.
- India (IND): $4.3B calculated opportunity across 4 products.

## Growth stars

- HS 294190: +177.0% average CAGR, $989.9M calculated opportunity.
- HS 382200: +85.0% average CAGR, $2.0B calculated opportunity.
- HS 382319: +31.3% average CAGR, $1.0B calculated opportunity.
- HS 381512: +20.4% average CAGR, $2.1B calculated opportunity.
- HS 382499: +19.4% average CAGR, $20.3B calculated opportunity.
- HS 310530: +16.0% average CAGR, $1.3B calculated opportunity.
- HS 300290: +11.7% average CAGR, $1.0B calculated opportunity.
- HS 330499: +5.2% average CAGR, $6.2B calculated opportunity.
- HS 290919: +4.7% average CAGR, $1.3B calculated opportunity.
- HS 300212: +1.3% average CAGR, $7.8B calculated opportunity.

## Diversification opportunities

- HS 300490: 13 buyer markets, $90.8B calculated opportunity.
- HS 382499: 11 buyer markets, $20.3B calculated opportunity.
- HS 300439: 5 buyer markets, $11.0B calculated opportunity.
- HS 300215: 3 buyer markets, $12.4B calculated opportunity.
- HS 300220: 3 buyer markets, $11.4B calculated opportunity.
- HS 330499: 3 buyer markets, $6.2B calculated opportunity.
- HS 300212: 2 buyer markets, $7.8B calculated opportunity.
- HS 330300: 2 buyer markets, $4.1B calculated opportunity.
- HS 284410: 2 buyer markets, $2.6B calculated opportunity.
- HS 300214: 1 buyer markets, $4.9B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.